Clinical trials: Gastric Cancer Third Line
Gastric Adenocarcinoma
A Study of Disitamab Vedotin, Tunlametinib, and PD-1 Antibody for Advanced Gastric Cancer
The goal of this clinical trial is to learn if the combination of disitamab vedotin, tunlametinib, and a PD-1 antibody works to treat HER2-overexpressing advanced gastric cancer in patients who have already received at least two…
- Trial name
- DTP-HER2 (NCT07507526)
- Testing
- Tunlametinib+PD-1 mAb
- Where
- China
- Volunteers
- 76 people
- Sponsor
- Sun Yat-sen University
Gastric Carcinoma
Apatinib Versus Placebo as a Third Line Treatment in Patients With Advanced or Metastatic Gastric Cancer
Apatinib is a tyrosin-inhibitor agent targeting at vascular endothelial growth factor receptor (VEGFR), and it's anti-angiogenesis effect has been viewed in preclinical tests.
- Trial name
- NCT00970138
- Testing
- apatinib tablet
- Where
- China
- Volunteers
- 141 people
- Sponsor
- Fudan University
Stomach Neoplasms
The Study of Apatinib Plus CIK as the Third Line Therapy for Patients With Advanced Gastric Cancer
The purpose of this study is to evaluate the safety and efficacy of Apatinib combined with cytokine-induced killer cell (CIK) vs Apatinib as the third line therapy for patients with advanced gastric cancer.
- Trial name
- NCT02485015
- Testing
- Cytokine-Induced Killer Cells, Apatinib
- Volunteers
- 80 people
- Sponsor
- The First People's Hospital of Changzhou
Adenocarcinoma, Scirrhous, Linitis Plastica
A Phase II Study to Evaluate Efficacy and Safety of Dovitinib (TKI258) in Advanced Scirrhous Gastric Carcinoma Patients
This is a prospective, open-label, single-arm, non-randomized, multi-center, phase II proof of concept (PoC) study with a two-stage design and Bayesian interim monitoring to evaluate efficacy and safety of single agent TKI258 in…
- Conditions
- Adenocarcinoma, Scirrhous, Linitis Plastica, Stomach Neoplasms, Stomach Diseases
- Trial name
- NCT01576380
- Testing
- TKI258
- Where
- 8 sites in Japan
- Volunteers
- 11 people
- Sponsor
- Novartis Pharmaceuticals
c-MET Positive Gastric Cancer
A Pilot Study of Crizotinib in Patients With c-MET Positive Gastric Adenocarcinoma as a Third-line Chemotherapy
This is a pilot study of crizotinib in patients with c-MET positive gastric adenocarcinoma.
- Trial name
- NCT02435108
- Testing
- crizotinib
- Where
- South Korea
- Volunteers
- 2 people
- Sponsor
- Samsung Medical Center
Metastatic Oesogastric Adenocarcinoma
Trifluridine/Tipiracil + Fruquintinib Versus Trifluridine/Tipiracil Alone for Metastatic Oeso-gastric Adenocarcinoma
Advanced cancer of the stomach and the gastro-esophageal junction (G/GEJ) remains a very serious disease. Today, only about 10-15% of patients are alive after 5 years.
- Trial name
- FRUQUITAS (NCT07270991)
- Testing
- trifluridine/tipiracil, fruquintinib
- Where
- 64 sites in France, Germany
- Volunteers
- 324 people
- Sponsor
- Federation Francophone de Cancerologie Digestive
Stomach Neoplasms
Irinotecan as 3rd Line Therapy in Gastric Cancer
Gastric cancer is the leading cause of cancer death in China. Most patients are unresectable or metastatic disease at the time of diagnosis. Systemic therapy was required for the patients with advanced stage.
- Trial name
- NCT02662959
- Testing
- Irinotecan
- Where
- China
- Volunteers
- 93 people
- Sponsor
- Fudan University
Gastric Cancer (GC)
To Evaluate the Safety and Tolerability of Study Drug as a Third-line and Beyond Therapy for Recurrent or Metastatic Gastric Cancer
This study aims to evaluate the safety and tolerability of JPI-547 in combination with irinotecan as a third-line and beyond therapy for recurrent or metastatic gastric cancer
- Trial name
- NCT07364422
- Testing
- JPI-547, Irinotecan (drug)
- Where
- South Korea
- Volunteers
- 49 people
- Sponsor
- Onconic Therapeutics Inc.
Gastric Cancer
Phase II Study of Liposomal Irinotecan for Advanced Refractory Gastric Cancer
To evaluate the objective response rate (ORR) and disease control rate (DCR) of liposomal irinotecan monotherapy in the treatment of recurrent/refractory advanced gastric cancer.
- Trial name
- NCT06437678
- Testing
- Liposomal Irinotecan Hydrochloride
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Zhejiang Cancer Hospital
Gastric Cancer Adenocarcinoma Metastatic
Trifluridine/tipiracil (TAS-102), Bevacizumab, and Camrelizumab As Third-line or Later-line Therapy of Gastric Cancer
For patients with metastatic gastric cancer, the efficacy of current standard treatments outlined in the guidelines is far from meeting the clinical demand.
- Trial name
- NCT06711471
- Testing
- trifluridine/tipiracil (TAS-102), bevacizumab plus camrelizumab
- Where
- China
- Volunteers
- 31 people
- Sponsor
- LIN YANG
Gastric Cancer, Metastasis
Apatinib Monotherapy Versus Apatinib Combined With Camrelizumab for Third-line Treatment of Metastatic Gastric Cancer
This open, single-center, randomized phase II study was to evaluate the clinical benefit of apatinib plus camrelizumab which is an anti-Programmed cell death-1 (PD-1) monoclonal antibody, versus apatinib in patients with…
- Trial name
- NCT05095636
- Testing
- Apatinib Mesylate, Camrelizumab
- Where
- China
- Volunteers
- 102 people
- Sponsor
- Fudan University
Metastatic Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma
Camrelizumab Combined With Apatinib Versus Apatinib Alone in the Third-line Treatment of Metastatic Gastric Cancer
This is a study of Camrelizumab combined with Apatinib versus Apatinib alone in the third-line treatment of metastatic gastric cancer.
- Trial name
- NCT05342389
- Testing
- Camrelizumab, Apatinib Mesylate
- Where
- China
- Volunteers
- 68 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Gastric Cancer, Ramucirumab
Folfiri as Third Line of Treatment
The aim of this study is to investigate the activity of Folfiri as Third line of treatment in mGC progressed after ramuciramb-based second line.
- Conditions
- Gastric Cancer, Ramucirumab, Third Line
- Trial name
- NCT03486379
- Volunteers
- 26 people
- Sponsor
- IRCCS Cancer Referral Center of Basilicata
Advanced Cervical Cancer
Combination of Metronomic Capecitabine With Camrelizumab for Treatment of Refractory Solid Tumor Trial (Cohort 1)
This is a single center phase 1 trail to observe safety and efficacy of metronomic capecitabine plus PD-L1 antibody camrelizumab as third-line regimen to treat HER2 negative advanced gastric cancer patients.
- Trial name
- NCT04508686
- Testing
- Capecitabine, camrelizumab
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Ruijin Hospital
Advanced Gastric Cancer
A Prospective, Single-arm, Exploratory Study of Trifluridine/Tipiracil (TAS-102) Combined With Apatinib as Third-line Therapy for Advanced Gastric Cancer
To evaluate the efficacy and safety of trifluridine/tipiracil (TAS-102) combined with apatinib as third-line therapy for advanced gastric cancer
- Trial name
- NCT07371871
- Testing
- Trifluridine/Tipiracil (TAS-102) combined with Apatinib
- Volunteers
- 30 people
- Sponsor
- Anhui Provincial Cancer Hospital
Unresectable, Recurrent, Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma, Gastric Cancer Third Line
Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300)
The purpose of this study was to demonstrate superiority of treatment with avelumab plus best supportive care (BSC) versus physician's choice (chosen from a pre-specified list of therapeutic options) plus BSC.
- Trial name
- NCT02625623
- Testing
- Avelumab, Irinotecan, Paclitaxel
- Where
- 75 sites in United States, Australia and 8 more
- Volunteers
- 371 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.